Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03796585 · ClinicalTrials.gov registry record · NA
Assessing Barriers and Increasing Use of Immunization Registries in Pharmacies
A NA study, sponsored by Auburn University.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
NCT03796585: Completed NA study, sponsored by Auburn University.
NCT03796585 is a NA study that has completed, run by Auburn University. The registered enrollment target is 52 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03796585, a NA study, has completed, sponsored by Auburn University.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to identify barriers to utilization of immunization registries within a pharmacy context and tailor the information into a novel immunization registry training program.
Primary Outcome
The change in the number of participant pharmacies enrolled in the Alabama immunization registry from baseline to 3 months.
Interventions
- BEHAVIORAL Immunization Registry Training
- BEHAVIORAL Informational flyer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2019-01-10 |
| Est. Completion | 2019-09-15 |
| Phase | NA |
What the finished NCT03796585 record still lists
NCT03796585 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Immunization Registry Training is the first listed.
NCT03796585 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03796585 about?
NCT03796585 is a clinical study titled "Assessing Barriers and Increasing Use of Immunization Registries in Pharmacies". The purpose of this study is to identify barriers to utilization of immunization registries within a pharmacy context and tailor the information into a novel immunization registry training program.
What is the current status of trial NCT03796585?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2019-01-10. Estimated completion is 2019-09-15.
What interventions are being tested in trial NCT03796585?
The interventions under investigation include: Immunization Registry Training (BEHAVIORAL), Informational flyer (BEHAVIORAL).
Who is sponsoring clinical trial NCT03796585?
This trial is sponsored by Auburn University, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03796585's enrollment target sits among peer trials
52 1272nd of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI